Ara
Toplam kayıt 1558, listelenen: 1511-1520
A multicenter study of self-limited epilepsy with centrotemporal spikes: Effectiveness of antiseizure medication with respect to spike-wave index
(Elsevier Inc., 2024)
Background: There is no certain validated electroencephalographic (EEG) parameters for outcome prediction in children with self-limited epilepsy with centrotemporal spikes. To assess the effectiveness of antiseizure ...
Clinical research clinical performance of posterior indirect resin composite restorations with the proximal box elevation technique: A prospective clinical trial up to 3 years
(Quintessence Publishing Co, Inc, 2024)
Purpose: The study evaluated the clinical performance of partial indirect resin composite (PIRC) restorations with "proximal box elevation" (PBE) placed in molars. Materials and Methods: Sixty-three patients received 80 ...
Unveiling the Nexus of conflict, communication and media
(İstanbul University, Faculty of Communication, 2023)
...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)
Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ...
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...
Efficacy of one-hour negative pressure wound therapy and magnetic field energy in wound healing
(MA Healthcare Ltd, 2024)
Objective: Wound healing is an important aspect of health but needs further research to identify the effects and interactions of different treatment approaches on healing. The aims of this study were to investigate the ...